GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?

Current Topics in Medicinal Chemistry

Volumn 10, Issue 8, 2010, Pages 799-813

  Nevalainen, Tapio ^a   Irving, Andrew J ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cannabinoid; GPR55; Lysophosphatidylinositol

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALSENILIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CX3CR1; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; INOSITOL PHOSPHATE; INTEGRIN; LIGAND; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDYLINOSITOL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOACYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C; PROTEIN CDC42; PURINERGIC RECEPTOR; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHODOPSIN; RIMONABANT; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BONE METABOLISM; BREAST CANCER; CELL MIGRATION; CHROMOSOME 2Q; ENCEPHALITIS; ENDOTHELIUM CELL; GENE MAPPING; GENOME; HUMAN; NEUROPATHIC PAIN; NONHUMAN; OBESITY; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; VASODILATATION;

ANIMALS; CANNABINOIDS; HUMANS; LYSOPHOSPHOLIPIDS; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHOLIPID; TRANSCRIPTION FACTORS;

EID: 78649689791     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791164229     Document Type: Article

References (133)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564.
2. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
3. Di Marzo, V.; Goparaju, S. K.; Wang, L.; Liu, J.; Batkai, S.; Jarai, Z.; Fezza, F.; Miura, G. I.; Palmiter, R. D.; Sugiura, T.; Kunos, G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 2001, 410, 822-825.
4. Di Marzo, V.; Goparaju, S. K.; Wang, L.; Liu, J.; Batkai, S.; Jarai, Z.; Fezza, F.; Miura, G. I.; Palmiter, R. D.; Sugiura, T.; Kunos, G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 2001, 410, 822-825.
5. Mbvundula, E. C.; Rainsford, K. D.; Bunning, R. A. D. Cannabinoids in pain and inflammation. Inflammopharmacology, 2004, 12, 99-114.
6. Mackie, K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 101-122.
7. Bifulco, M.; Laezza, C.; Pisanti, S.; Gazzerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br. J. Pharmacol., 2006, 148, 123-135.
8. Begg, M.; Pacher, P.; Batkai, S.; Osei-Hyiaman, D.; Offertaler, L.; Mo, F. M.; Liu, J.; Kunos, G. Evidence for novel cannabinoid receptors. Pharmacol. Ther., 2005, 106, 133-145.
9. Jarai, Z.; Wagner, J. A.; Varga, K.; Lake, K. D.; Compton, D. R.; Martin, B. R.; Zimmer, A. M.; Bonner, T. I.; Buckley, N. E.; Mezey, E.; Razdan, R. K.; Zimmer, A.; Kunos, G. Cannabinoidinduced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA, 1999, 96, 14136-14141.
10. Mackie, K.; Stella, N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J., 2006, 8, E298-306.
11. Offertaler, L.; Mo, F.; Batkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B. R.; Bukoski, R. D.; Kunos, G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol., 2003, 63, 699-705.
12. Wagner, J. A.; Varga, K.; Jarai, Z.; Kunos, G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension, 1999, 33, 429-434.
13. Walter, L.; Franklin, A.; Witting, A.; Wade, C.; Xie, Y.; Kunos, G.; Mackie, K.; Stella, N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 2003, 23, 1398-1405.
14. Breivogel, C. S.; Griffin, G.; Di Marzo, V.; Martin, B. R. Evidence for a new g protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 2001, 60, 155-163.
15. Monory, K.; Th. Tzavara, E.; Lexime, J.; Ledent, C.; Parmentier, M.; Borsodi, A.; Hanoune, J. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem. Biophys. Res. Commun., 2002, 292, 231-235.
16. Marzo, D. V.; Breivogel, C. S.; Tao, Q.; Bridgen, D. T.; Razdan, K.R.; Zimmer, M. A.; Zimmer, A.; Martin, R. B. Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice. J. Neurochem., 2000, 75, 2434-2444.
17. Hájos, N.; Ledent, C.; Freund, T. F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience, 2001, 106, 1-4.
18. LoVerme, J.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The search for the palmitoylethanolamide receptor. Life Sci., 2005, 77, 1685-1698.
19. Cristino, L.; de Petrocellis, L.; Pryce, G.; Baker, D.; Guglielmotti, V.; Di Marzo, V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience, 2006, 139, 1405-1415.
20. Kim, S. R.; Chung, Y. C.; Chung, E. S.; Park, K. W.; Won, S. Y.; Bok, E.; Park, E. S.; Jin, B. K. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. Mol. Neurobiol., 2007, 35, 245-254.
21. Zygmunt, P. M.; Petersson, J.; Andersson, D. A.; Chuang, H.; Sorgard, M.; Di Marzo, V.; Julius, D.; Hogestatt, E. D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999, 400, 452-457.
22. Carbonare, M. D.; Del Giudice, E.; Stecca, A.; Colavito, D.; Fabris, M.; D'Arrigo, A.; Bernardini, D.; Dam, M.; Leon, A. A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with antiinflammatory properties: a neglected story. J. Neuroendocrinol., 2008, 20, 26-34.
23. Maccarrone, M.; Pauselli, R.; Di Rienzo, M.; Finazzi-Agro, A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem. J., 2002, 366, 137-144.
24. Terrazzino, S.; Berto, F.; Carbonare, M. D.; Fabris, M.; Guiotto, A.; Bernardini, D.; Leon, A. Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression. FASEB J., 2004, 18, 1580-1582.
25. Rodriguez, D. F.; Navarro, M.; Gomez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodriguez, E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; Kathuria, S.; Gall, C.; Piomelli, D. An anorexic lipid mediator regulated by feeding. Nature, 2001, 414, 209-212.
26. Ho, W.; Barrett, D. A.; Randall, M. D. 'Entourage' effects of Npalmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol., 2008, 155, 837-846.
27. O'Sullivan, S. E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol., 2007, 152, 576-582.
28. Berger, J.; Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
29. Feige, J. N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res., 2006, 45, 120-159.
30. Kozak, K. R.; Gupta, R. A.; Moody, J. S.; Ji, C.; Boeglin, W. E.; DuBois, R. N.; Brash, A. R.; Marnett, L. J. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J. Biol. Chem., 2002, 277, 23278-23286.
31. Fu, J.; Gaetani, S.; Oveisi, F.; Lo Verme, J.; Serrano, A.; Rodriguez, D. F.; Rosengarth, A.; Luecke, H.; Di Giacomo, B.; Tarzia, G.; Piomelli, D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR- α. Nature, 2003, 425, 90-93.
32. Guzmán, M.; Lo Verme, J.; Fu, J.; Oveisi, F.; Blázquez, C.; Piomelli, D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR- α). J. Biol. Chem., 2004, 279, 27849-27854.
33. Sun, Y.; Alexander, S. P. H.; Garle, M. J.; Gibson, C. L.; Hewitt, K.; Murphy, S. P.; Kendall, D. A.; Bennett, A. J. Cannabinoid activation of PPAR α; a novel neuroprotective mechanism. Br. J. Pharmacol., 2007, 152, 734-743.
34. Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol., 2005, 67, 15-19.
35. Sun, Y.; Alexander, S. P. H.; Kendall, D. A.; Bennett, A. J. Cannabinoids and PPAR α signalling. Biochem. Soc. Trans., 2006, 34, 1095-1097.
36. Burstein, S. PPAR-α: A nuclear receptor with affinity for cannabinoids. Life Sci., 2005, 77, 1674-1684.
37. Bouaboula, M.; Hilairet, S.; Marchand, J.; Fajas, L.; Fur, G. L.; Casellas, P. Anandamide induced PPAR α transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol., 2005, 517, 174-181.
38. Rockwell, C. E.; Snider, N. T.; Thompson, J. T.; Vanden Heuvel, J. P.; Kaminski, N. E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor {gamma} independently of cannabinoid receptors 1 and 2. Mol. Pharmacol., 2006, 70, 101-111.
39. Liu, J.; Li, H.; Burstein, S. H.; Zurier, R. B.; Chen, J. D. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol., 2003, 63, 983-992.
40. O'Sullivan, S. E.; Kendall, D. A.; Randall, M. D. Further Characterization of the Time-Dependent Vascular Effects of {Delta}9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 2006, 317, 428-438.
41. S. E.; Bennett, A. J.; Kendall, D. A.; Randall, M. D. Cannabinoids and peroxisome proliferatoractivated receptor gamma (PPAR α). symposium on the cannabinoids, Tihany, Hungary, International Cannabinoid Research Society, page 59. 2006.
42. Matias, I.; Gonthier, M.; Orlando, P.; Martiadis, V.; De Petrocellis, L.; Cervino, C.; Petrosino, S.; Hoareau, L.; Festy, F.; Pasquali, R.; Roche, R.; Maj, M.; Pagotto, U.; Monteleone, P.; Di Marzo, V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and {beta}-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab., 2006, 91, 3171-3180.
43. Wise, A.; Brown, A. J. Identification of modulators of GPR55 activity. PCT Int. Appl. 2001086305, 2001.
44. Drmota, T.; Greasley, P.; Groblewski, T. Screening assays for cannabinoid-ligand type modulators of GPR55. PCT Int. Appl. 2004074844, 2004.
45. Overton, H. A.; Babbs, A. J.; Doel, S. M.; Fyfe, M. C.; Gardner, L. S.; Griffin, G.; Jackson, H. C.; Procter, M. J.; Rasamison, C. M.; Tang-Christensen, M.; Widdowson, P. S.; Williams, G. M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell. Metab., 2006, 3, 167-175.
46. Overton, H. A.; Fyfe, M. C.; Reynet, C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 2008, 153 (Suppl 1), S76-81.
47. Brown, A. J. Novel cannabinoid receptors. Br. J. Pharmacol., 2007, 152, 567-575.
48. R. A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci., 2009, 30, 156-163.
49. Brown, A. J.; Robin Hiley, C. Chapter 5 Is GPR55 an Anandamide Receptor? In: Vitamins & Hormones; Gerald, L., Ed.; Academic Press, USA 2009, vol. 81, pp 111-137.
50. Godewski, G.; Offertáler, L.; Wagner, J. A.; Kunos, G. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Lipid Mediat., 2009, 89, 105-111.
51. Sawzdargo, M.; Nguyen, T.; Lee, D. K.; Lynch, K. R.; Cheng, R.; Heng, H. H.; George, S. R.; O'Dowd, B. F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res., 1999, 64, 193-198.
52. McPartland, J. M.; Matias, I.; Di Marzo, V.; Glass, M. Evolutionary origins of the endocannabinoid system. Gene, 2006, 370, 64-74.
53. McPartland, J. M.; Norris, R. W.; Kilpatrick, C. W. Tempo and mode in the endocannaboinoid system. J. Mol. Evol., 2007, 65, 267-276.
54. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N. O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152, 1092-1101.
55. Joost, P.; Methner, A. Phylogenetic analysis of 277 human Gprotein- coupled receptors as a tool for the prediction of orphan receptor ligands. Genome Biol., 2002, 3, RESEARCH0063.
56. Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63, 1256-1272.
57. Altschul, S.; Madden, T.; Schaffer, A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., 1997, 25, 3389-3402.
58. Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H.; Ling, L. Kynurenic acid as a ligand for orphan G proteincoupled receptor GPR35. J. Biol. Chem., 2006, 281, 22021-22028.
59. Noguchi, K.; Ishii, S.; Shimizu, T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem., 2003, 278, 25600-25606.
60. Kotarsky, K.; Boketoft, A.; Bristulf, J.; Nilsson, N. E.; Norberg, A.; Hansson, S.; Owman, C.; Sillard, R.; Leeb-Lundberg, L. M. F.; Olde, B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther., 2006, 318, 619-628.
61. Petitet, F.; Donlan, M.; Michel, A. GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem. Biol. Drug Des., 2006, 67, 252-253.
62. Waldeck-Weiermair, M.; Zoratti, C.; Osibow, K.; Balenga, N.; Goessnitzer, E.; Waldhoer, M.; Malli, R.; Graier, W. F. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptortriggered repression. J. Cell. Sci., 2008, 121, 1704-1717.
63. Pietr, M.; Kozela, E.; Levy, R.; Rimmerman, N.; Lin, Y. H.; Stella, N.; Vogel, Z.; Juknat, A. Differential changes in GPR55 during microglial cell activation. FEBS Lett., 2009,
64. Wise, A.; Brown, A. James Identification of modulators of GPR55 activity. PCT Int. Appl. 2001086305, 2001.
65. Gratzke, C.; Weinhold, P.; Selwood, D.; Stief, C. G.; Andersson, K. E.; Hedlund, P. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Eur. Urol. Suppl., 2009, 8, 271-271.
66. Daly, C. J.; Wallace, G.; White, K.; Henstridge, C.; Irving, A.; McGrath, J. C. Visualisation of vascular cannabinoid receptors and their potential interaction with α 1-adrenergic receptors. Vascular and Smooth Muscle Phys.Soc. Symposium. King's College London. Proc. Physiol. Soc., 2008, 13, PC4
67. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362, 928-934.
68. Henstridge, C. M.; Balenga, N. A.; Ford, L. A.; Ross, R. A.; Waldhoer, M.; Irving, A. J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J., 2009, 23, 183-193.
69. Henstridge, C. M.; Balenga, N. A. B.; Schröder, R.; Kargl, J. K.; Platzer, W.; Martini, L.; Arthur, S.; Penman, J.; Whistler, J. L.; Kostenis, E.; Waldhoer, M.; Irving, A. J. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br. J. Pharmacol., 2010, [Epub ahead of print], DOI:10.1111/j.1476-5381.2009.00625.x
70. Johns, D. G.; Behm, D. J.; Walker, D. J.; Ao, Z.; Shapland, E. M.; Daniels, D. A.; Riddick, M.; Dowell, S.; Staton, P. C.; Green, P.; Shabon, U.; Bao, W.; Aiyar, N.; Yue, T. L.; Brown, A. J.; Morrison, A. D.; Douglas, S. A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol., 2007, 152, 825-831.
71. Lauckner, J. E.; Jensen, J. B.; Chen, H. Y.; Lu, H. C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA, 2008, 105, 2699-2704.
72. Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D. G.; Caldwell, J. S.; Chen, Y. A. Lipid G protein-coupled receptor ligand identification using {beta}-arrestin pathhunterTM Assay. J. Biol. Chem., 2009, 284, 12328-12338.
73. Whyte, L.; Ryberg, E.; Sims, N. A.; Ridge, S.; Mackie, K.; Greasley, P.; Ross, R. A.; Rogers, M. J. GPR55: A novel cannabinoid receptor involved in the regulation of osteoclast function and bone mass. Bone, 2009, 44, S138-S138.
74. Oka, S.; Kimura, S.; Toshida, T.; Ota, R.; Yamashita, A.; Sugiura, T. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J. Biochem., 2010, Jan 4. [Epub ahead of print], DOI:10.1093/jb/mvp208.
75. Patny, A.; Desai, P. V.; Avery, M. A. Homology modeling of Gprotein- coupled receptors and implications in drug design. Curr. Med. Chem., 2006, 13, 1667-1691.
76. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-745.
77. Okada, T.; Sugihara, M.; Bondar, A. N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J. Mol. Biol., 2004, 342, 571-583.
78. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human beta2 adrenergic Gprotein- coupled receptor. Nature, 2007, 450, 383-387.
79. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science, 2007, 318, 1258-1265.
80. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491.
81. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322, 1211-1217.
82. Murakami, M.; Kouyama, T. Crystal structure of squid rhodopsin. Nature, 2008, 453, 363-367.
83. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H. W.; Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature, 2008, 454, 183-187.
84. Kobilka, B.; Schertler, G. F. X. New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol. Sci., 2008, 29, 79-83.
85. Gloriam, D. E.; Foord, S. M.; Blaney, F. E.; Garland, S. L. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem., 2009, 52(14), 4429-4442.
86. McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Abood, M. E. An aromatic microdomain at the cannabinoid CB1 receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem., 2003, 46, 5139-5152.
87. Shim, J.; Welsh, W. J.; Howlett, A. C. Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction. Peptide Sci., 2003, 71, 169-189.
88. Salo, O. M. H.; Lahtela-Kakkonen, M.; Gynther, J.; Järvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem., 2004, 47, 3048-3057.
89. Salo, O. M. H.; Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Järvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem. 2005, 48, 7166-7171.
90. Xie, X.; Chen, J.; Billings, E. M. 3D structural model of the Gprotein- coupled cannabinoid CB2 receptor. Proteins: Struct. Funct. Genet., 2003, 53, 307-319.
91. Montero, C.; Campillo, N. E.; Goya, P.; Páez, J. A. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. Eur. J. Med. Chem., 2005, 40, 75-83.
92. Tuccinardi, T.; Ferrarini, P. L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. receptor modeling and automated docking analysis. J. Med. Chem., 2006, 49, 984-994.
93. Gonzalez, A.; Duran, L. S.; Araya-Secchi, R.; Garate, J. A.; Pessoa-Mahana, C. D.; Lagos, C. F.; Perez-Acle, T. Computational modeling study of functional microdomains in cannabinoid receptor type 1. Bioorg. Med. Chem., 2008, 16, 4378-4389.
94. J. Transmembrane helical domain of the cannabinoid CB1 receptor. Biophys. J., 2009, 96, 3251-3262.
95. Ahn, K. H.; Bertalovitz, A. C.; Mierke, D. F.; Kendall, D. A. Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol. Pharmacol., 2009, 76, 833-842.
96. Diaz, P.; Phatak, S. S.; Xu, J.; Astruc-Diaz, F.; Cavasotto, C. N.; Naguib, M. 6-methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. J. Med. Chem., 2009, 52, 433-444.
97. Brown, A., James; Ueno, S.; Suen, K.; Dowell, S. J.; Wise, A. Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. 2005 symposium on the cannabinoids, Florida, USA, International Cannabinoid Research Society, page 16.
98. Sjögren, S.; Ryberg, E.; Lindblom, A.; Larsson, N.; Åstrand, A.; Hjorth, S.; Andersson, A.-K.; Groblewski, T.; Greasley, P. A new receptor for cannabinoid ligands. 2005 symposium on the cannabinoids, florida, USA, International Cannabinoid Research Society, page 106.
99. Greasley, P. J.; Åstrand, A.; Linblom, A.; Sjöqvist, P.-O.; Hjort, S.; Sjögren, S. A role for GPR55 in mediating blood pressure responses. 2008 symposium on the cannabinoids, Aviemore, Scotland, International Cannabinoid Research Society, page 89.
100. Staton, P. C.; Hatcher, J. P.; Walker, D. J.; Morrison, A. D.; Shapland, E. M.; Hughes, J. P.; Chong, E.; Mander, P. K.; Green, P. J.; Billinton, A.; Fulleylove, M.; Lancaster, H. C.; Smith, J. C.; Bailey, L. T.; Wise, A.; Brown, A. J.; Richardson, J. C.; Chessell, I. P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain, 2008, 139, 225-236.
101. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E.; Mechoulam, R.; Zimmer, A.; Bab, I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA, 2006, 103, 696-701.
102. Tam, J.; Ofek, O.; Fride, E.; Ledent, C.; Gabet, Y.; Muller, R.; Zimmer, A.; Mackie, K.; Mechoulam, R.; Shohami, E.; Bab, I. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol. Pharmacol., 2006, 70, 786-792.
103. Ford, L. A.; Roelofs, A. J.; Anavi-Goffer, S.; Mowat, L.; Simpson, D. G.; Irving, A. J.; Rogers, M. J.; Rajnicek, A. M.; Ross, R. A. A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarisation of human breast cancer cells. Br. J. Pharmacol. 2010, [Epub ahead of print], DOI:10.1111/j.1476-5381.2010.00743.x.
104. Corda, D.; Iurisci, C.; Berrie, C. P. Biological activities and metabolism of the lysophosphoinositides and glycerophosphoinositols. Biochim. Biophys. Acta, 2002, 1582, 52-69.
105. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: A possible natural ligand for GPR55. J. Biochem., 2009, 145, 13-20.
106. Rimmerman, N.; Hughes, H.V.; Bradshaw, H. B.; Pazos, M. X.; Mackie, K.; Prieto, A. L.; Walker, J. M. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. Br. J. Pharmacol., 2008, 153, 380-389.
107. VanMiddlesworth, F.; Lopez, M.; Zweerink, M.; Edison, A. M.; Wilson, K. Chemicoenzymic synthesis of lysofungin. J. Org. Chem., 1992, 57, 4753-4754.
108. Billah, M.; Lapetina, E.; Cuatrecasas, P. Phospholipase A2 and phospholipase C activities of platelets. Differential substrate specificity, Ca2+ requirement, pH dependence, and cellular localization. J. Biol. Chem., 1980, 255, 10227-10231.
109. Kobayashi, T.; Kishimoto, M.; Okuyama, H. Phospholipases involved in lysophosphatidylinositol metabolism in rat brain. J. Lipid Mediat. Cell Signal, 1996, 14, 33-37.
110. Ueda, H.; Kobayashi, T.; Kishimoto, M.; Tsutsumi, T.; Okuyama, H. A possible pathway of phosphoinositide metabolism through EDTA-insensitive phospholipase A1 followed by lysophosphoinositide- specific phospholipase C in rat brain. J. Neurochem., 1993, 61, 1874-1881.
111. Ueda, H.; Kobayashi, T.; Kishimoto, M.; Tsutsumi, T.; Okuyama, H. A possible pathway of phosphoinositide metabolism through EDTA-insensitive phospholipase A1 followed by lysophosphoinositide- specific phospholipase C in rat brain. J. Neurochem., 1993, 61, 1874-1881.
112. Sugiura, T.; Kudo, N.; Ojima, T.; Mabuchu-Itoh, K.; Yamashita, A.; Waku, K. Coenzyme A-dependent cleavage of membrane phospholipids in several rat tissues: ATP-independent acyl-CoA synthesis and the generation of lysophospholipids. Biochim. Biophys. Acta Lipids Lipid Metabol., 1995, 1255, 167-176.
113. Yamashita, A.; Watanabe, M.; Sato, K.; Miyashita, T.; Nagatsuka, T.; Kondo, H.; Kawagishi, N.; Nakanishi, H.; Kamata, R.; Sugiura, T.; Waku, K. Reverse reaction of lysophosphatidylinositol acyltransferase. Functional reconstitution of coenzyme A-dependent transacylation system. J. Biol. Chem., 2003, 278, 30382-30393.
114. Murase, S.; Okuyama, H. A membrane-bound phospholipase C with an apparent specificity for lysophosphatidylinositol in porcine platelets. J. Biol. Chem., 1985, 260, 262-265.
115. Volwerk, J. J.; Shashidhar, M. S.; Kuppe, A.; Griffith, O. H. Phosphatidylinositol-specific phospholipase C from Bacillus cereus combines intrinsic phosphotransferase and cyclic phosphodiesterase activities: a phosphorus-31 NMR study. Biochemistry (NY), 1990, 29, 8056-8062.
116. Tsutsumi, T.; Kobayashi, T.; Miyashita, M.; Watanabe, S.; Homma, Y.; Okuyama, H. A Lysophosphoinositide-specific phospho-lipase C distinct from other phospholipase C families in rat brain. Arch. Biochem. Biophys., 1995, 317, 331-336.
117. Falasca, M.; Corda, D. Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur. J. Biochem., 1994, 221, 383-389.
118. Falasca, M.; Silletta, M. G.; Carvelli, A.; Di Francesco, A. L.; Fusco, A.; Ramakrishna, V.; Corda, D. Signalling pathways involved in the mitogenic action of lysophosphatidylinositol. Oncogene, 1995, 10, 2113-2124.
119. Metz, S. A. Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin release: A possible role for phospholipase A2 but not de novo synthesis of lysophospholipid in pancreatic islet function. Biochem. Biophys. Res. Commun., 1986, 138, 720-727.
120. Baran, D. T.; Kelly, A. M. Lysophosphatidylinositol: a potential mediator of 1,25-dihydroxyvitamin D-induced increments in hepatocyte cytosolic calcium. Endocrinology, 1988, 122, 930-934.
121. Ryu, S. B.; Karlsson, B. H.; Özgen, M.; Palta, J. P. Inhibition of phospholipase D by lysophosphatidylethanolamine, a lipid-derived senescenceretardant. Proc. Natl. Acad. Sci. USA, 1997, 94, 12717-12721.
122. Maingret, F.; Patel, A. J.; Lesage, F.; Lazdunski, M.; Honore, E. Lysophospholipids open the two-pore domain mechano-gated K+ channels TREK-1 and TRAAK. J. Biol. Chem., 2000, 275, 10128-10133.
123. Kiyotaka Matsumura.; Kenji Aketa, Activation of proteasome in sea urchin sperm by lysophosphatidylinositol and by sperm lipids. Dev. Growth Differ., 1991, 33, 259-266.
124. Soga, T.; Ohishi, T.; Matsui, T.; Saito, T.; Matsumoto, M.; Takasaki, J.; Matsumoto, S.; Kamohara, M.; Hiyama, H.; Yoshida, S.; Momose, K.; Ueda, Y.; Matsushime, H.; Kobori, M.; Furuichi, K. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun., 2005, 326, 744-751.
125. Filthuth, E.; Eibl, H. Synthesis of enantiomerically pure lysophosphatidylinositols and alkylphosphoinositols. Chem. Phys. Lipids, 1992, 60, 253-261.
126. Myher, J. J.; Kuksis, A. Molecular species of plant phosphatidylinositol with selective cytotoxicity towards tumor cells. Biochim. Biophys. Acta Lipids Lipid Metabol., 1984, 795, 85-90.
127. D'Arrigo, P.; Servi, S. Using phospholipases for phospholipid modification. Trends Biotechnol., 1997, 15, 90-96.
128. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M. G.; Barak, L. S.; Abood, M. E. Atypical responsiveness of the orphan receptor GPR-55 to cannabinoid ligands. J. Biol. Chem., 2009, 284, 29817-29827.
129. Xiao, Y.; Chen, Y.; Kennedy, A. W.; Belinson, J.; Xu, Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann. N. Y. Acad. Sci., 2000, 905, 242-259.
130. Peterson, B. L.; Cummings, B. S. A review of chromatographic methods for the assessment of phospholipids in biological samples. Biomed. Chromatogr., 2006, 20, 227-243.
131. Bligh, E. G.; Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol., 1959, 37, 911-917.
132. Brügger, B.; Erben, G.; Sandhoff, R.; Wieland, F. T.; Lehmann, W. D. Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. Proc. Natl. Acad. Sci. USA, 1997, 94, 2339-2344.
133. Xiao, Y.; Schwartz, B.; Washington, M.; Kennedy, A.; Webster, K.; Belinson, J.; Xu, Y. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal. Biochem., 2001, 290, 302-313.